Previous studies have shown that RhoE, an atypical member of the Rho GTPase family, may play an opposite role to RhoA in regulating cell proliferation and invasion. To explore the relationship between RhoE and the malignant phenotypes of human cancer, we have determined the expression patterns of RhoE in varying grade of human cancer tissues and tested the effects of RhoE expression in several RhoE underexpressing cancer cell lines. Systemic immunocytochemistry analyses of gastric, colorectal, lung and breast carcinomas, respectively, showed that RhoE protein expression was significantly decreased in most cancer cases compared with that of adjacent normal tissues. Enhanced RhoE expression could markedly inhibit proliferation, migration and invasion and induce apoptosis of the cancer cells which have relatively low levels of endogenous RhoE expression. Wild-type p53 (wt-p53) could strongly increase RhoE expression in p53-transfected cells. Furthermore, the luciferase assays indicated that wt-p53 significantly enhanced the activities of RhoE promoter compared with mutant p53 (mt-p53) in PC3 cells (p53 null). Collectively, data are presented showing that RhoE may participate in human cancer progression and act as a candidate target of p53, and these findings also strongly suggest that RhoE may be a new candidate tumor suppressor and could serve as a potential target in the gene therapy of cancer.
Introduction
Rho family GTPases, a part of the Ras superfamily which are involved in regulating multiple aspects of cell functions such as cell proliferation, survival, adhesion and migration, are intimately relevant in tumor initiation and tumor progression (1) (2) (3) (4) (5) . Most members of the Rho family can cycle between an active, GTP-bound conformation and an inactive, GDP-bound conformation, and this GTP-binding and GTP-hydrolysis process is tightly regulated by various classes of regulators including the guanine nucleotide exchange factors and GTPase-activating proteins. The best characterized members of the Rho family include Rho (A, B and C), Rac (1, 2 and 3) and Cdc42. RhoE is a unique member of the Rnd subfamily, a distinct branch of Rho family proteins that bind, but do not hydrolyze GTP, thus remains constitutively active upon expression without the regulation by guanine nucleotide exchange factors and GTPase-activating proteins (6) (7) (8) (9) . In addition, the carboxy-terminal sequence of RhoE is farnesylated while most Rho family proteins are modified by geranylation. These observations suggest that the function and regulation of RhoE may be different from other Rho family members (6) .
There are some studies on the role of RhoE in human malignancies. Several reports have examined RhoE expression patterns in tumor tissues, but the results were contradictory (7, (10) (11) (12) . RhoE expression level does not change in response to serum stimulation, however, it can be enhanced by DNA-damaging agents such as cisplatin or UBV (9) . Tumor suppressor p53 can also induce cell cycle arrest at G1 and allow cells to repair DNA damage induced by ionizing radiation, UV light or chemotherapeutic drugs before proceeding to DNA replication (13) (14) (15) . Ongusaha et al have shown that RhoE is a transcriptional target of p53 and can inhibit ROCK1-mediated apoptosis in response to genotoxic stress (16 In the present study we systematically investigated the expression levels of RhoE in human gastric, colorectal, lung and breast cancer tissues by using tissue microarrays and explored the effect of RhoE expression on the growth and invasion phenotypes of the cancer cell lines. We further attribute the relatively reduced RhoE expression to the reduction of p53 transcription activity in the cancer cells and present evidence that RhoE expression could be affected by p53 mutation. These findings may partly explain the mechenism of RhoE downregulation in some cancers.
Materials and methods
Cell culture. Human embryonic kidney cells 293, gastric cancer cell lines MKN45 and AGS, colorectal cancer cell lines SW480 and LOVO, liver cancer cell lines HepG2 and SMMC-7721, lung cancer cell lines A549 and SPCA1, and the prostate carcinoma cell line PC3, were preserved at our institute. All cell lines were maintained in RPMI-1640 medium (Invitrogen Corporation, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA), 100 U/ml penicillin G sodium, and 100 µg/ml streptomycin sulfate (Sigma, St Louis, MO, USA). Cells were grown at 37˚C in a humidified atmosphere containing 5% CO 2 .
Plasmids and transfection. Expression vectors pCDNA3.0-RhoE, PEGFP, MIEG3-wt-p53, p21-promoter-luc and PRL-TK were kindly provided by Professor Yi Zheng (Cincinnati Children's Hospital, Cincinnati, OH, USA). MIEG3-wt-p53 and PEGFP were digested with BamH1 and EcoR1 in order to construct the expression vector PEGFP-wt-p53. PEGFPmt-p53 plasmids that mutated at p53 hot points (175, 248, 273, 282, 175/248, 175/273, 175/282, 248/273, 248/282, 273/282) were constructed on the basis of PEGFP-wt-p53. PGL3-RhoEpromoter-3000-luc was stored in our laboratory. Cells were transfected by Lipofectamine 2000 (Invitrogen), and stable transfection cell lines were selected with G418 (Gibco).
Immunohistochemistry. Tissue microarrays were obtained from Cybrdi Co. (Xi'an, China), containing 74 cases of gastric carcinoma, 32 cases of colorectal carcinoma, 62 cases of lung carcinoma and 34 cases of breast carcinoma. All were matched with the adjacent cancerous tissues and their clinicopathological grades were evaluated using WHO standards. The tissue microarrays were evaluated by three pathologists who did not know the information of the slides. IHC studies were performed using a standard avidin-biotin complex immunoperoxidase method. Briefly, tissue sections were deparaffinized in xylene and rehydrated with a series of decreasing alcohol concentrations and the endogenous peroxidase activity was inhibited with a 3% solution of H 2 O 2 for 10 min. For antigen retrieval, tissue slides were treated in citrate buffer (pH 6.0) with microwave for 10 min. The detection was then performed following the instruction of mouse streptavidin-peroxidase immunostaining kit (SP-9000 Histostain-Plus Kit; Zhong Shan Goldbridge Biotechnology Co., Ltd, Beijing, China) containing normal goat serum, biotinylated secondary antibody and streptavidinperoxidase complex. The slides were independently incubated with anti-RhoE monoclonal antibody (05-723, clone 4, Upstate Biotechnology, Lake Placid, NY, USA) which were diluted 1:50 in PBS overnight at 4˚C. Pre-immune serum, instead of a primary antibody, was used as a negative control. Then the slides were stained with DAB (Pierce Biotechnology, Rockford, IL, USA), dehydrated, cleared and mounted with neutral balsam.
The ratio of positive cells per specimen was evaluated quantitatively and scored: 0 for staining ≤1%, 1 for staining of 2 to 25%, 2 for staining of 26 to 50%, 3 for staining of 51 to 75%, and 4 for staining >75% of the cells examined. Staining intensity was graded as follows: 0, no signal; 1, weak; 2, moderate; and 3, strong staining. Both scoring systems were utilized to evaluate the level of protein expression. A total score of 0 to 12 was finally calculated and graded as negative (-, 0-1); weak (+, 2-4); moderate (++, 5-8); and strong (+++, 9-12). This scoring system has been described previously.
Monolayer growth rate and cell cycle assay. Cells (500-1,000) were plated in 96-wells cell culture plate. Cell counting kit-8 (Dojindo, Kumamoto, Japan) was used to determine the monolayer culture growth rate. Cultures were assayed at 0, 1, 2, 3, 4, 5 or 6 days. Absorbance values were determined on the microplate reader (Bio-Rad Laboratories, Hercules, CA, USA) at 490 and 630 nm. Cell cycle profiles were measured by flow cytometry using propidium iodide (PI). Transfectants which were stable transfected with RhoE and pcDNA3.0, respectively, were starved for 24 h in 0.5% serum-containing medium and then were stimulated with 10% FBS before fixing with 70% ethanol at 4˚C overnight, washed with PBS, and stained with PI (50 µg/ml) in PBS supplemented with RNase (10 mg/ml) for 30 min. Flow cytometry was performed on a FACScan (Becton-Dickinson, Heidelberg, Germany) equipped with cellquest software, and cellular DNA content was determined for 1x10 4 cells.
In vitro apoptosis assay. Hoechst/PI staining and TUNEL experiments were performed to study cell apoptosis. First, cells were trypsinized and washed with PBS twice. For the Hoechst/PI staining, prepared cells were fixed in 100 µl PBS containing 0.1 µg Hoechst 33342 for 10 min at 37˚C. After centrifuging, cells were stained with PI. Next, the apoptotic cells were viewed and counted by fluorescent microscopy at once. For the TUNEL experiment, 1x10 5 prepared cells were added into 6-wells cell culture plates which were coated with thin slides. Cells were harvested for 48 h and then tested by chromogenic method TUNEL apoptosis detection kit (Beyotime, Jiangsu, China). Cells were fixed in 4% paraformaldehyde for 1 h, and then incubated in Biotin-UTP solution for 1 h at room temperature. After that, samples were incubated in streptavidin-HRP buffer and colored by DAB and hematoxylin. TUNEL-positive nuclei stained dark brown and TUNEL-negative nuclei stained blue. The sections were examined using light microscopy.
Invasion assay. Millicell hanging cell culture inserts (Millipore, Billerica, MA, USA) precoated with Matrigel (Becton-Dickinson) were put in a 24-well plate to perform cell invasion assays. Cells (1-1.5x10 4 per well) were suspended in 0.25 ml of culture medium with 1% FBS and added to the upper chamber. Medium (1.25 ml) supplemented with 10% FBS was plated in the bottom of the well. The invasion assay was carried out for 48 h in a humidified incubator. The cells that traversed the membrane pore and spread to the lower surface of the filters were stained with eosin for visualization and then counted in 10 random high power fields (x200).
Western blot analysis. Cells were lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.2 g/l sodium azide, 1 g/l SDS, 1% Triton X-100, together with a protease inhibitor mix (Calbiochem, La Jolla, CA, USA). Cellular protein was quantified by a BCA protein assay kit (Pierce). Equal amounts of proteins (30-40 µg) were fractionated by 8-15% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and then transferred to PVDF (Millipore). The sheets were pre-incubated in a mixture of PBS and 5% non-fat milk powder for 2 h at room temperature. For immunoblotting studies, membranes were incubated overnight at 4˚C with 5% non-fat milk powder containing the primary antibodies as following: antibodies against RhoE (05-723, clone 4, Upstate Biotechnology). After a TBS-0.05% Tween-20 wash, the sheets were incubated with an IRDye 800CW secondary antibody (LI-COR Biosciences, Lincoln, NE, USA) at room temperature for 1 h in a cassette. After incubation, the sheets were washed in TBS-0.05% Tween-20 also in a cassette and then detected by Odyssey infrared fluorescence scanner (LI-COR).
Dual-luciferase reporter assay. For dual-luciferase reporter assays, 1x10
5 cells per well in 24-well plates were seeded the day before transfection. Cells were transfected with 1.0 µg of p21-promoter-luc together with 0.2 µg PRL-TK or RhoE-promoter-luc 0.4 µg, wt-p53/mt-p53 1.0 µg together with 0.2 µg PRL-TK. The cells were harvested for 48 h and then detected by dual-luciferase reporter assay system kit (Promega, Madison, WI, USA). The luciferase activity was measured with the Synergy2 instrument (BioTek, Winnoski, VT, USA) equipped with Gen5 software. The firely luciferase expression was normalized to Renilla luciferase and reported as relative luciferase activity. Results are presented as means ± standard deviations (SD) of data from three dependent experiments.
RNA extraction and p53 mutation detection. The total RNA of 293, MKN45, AGS, SW480, LOVO, SPCA1, A549, HepG2 and SMMC-7721 was extracted using TRIzol (Invitrogen) according to the manufacturer's protocol. The quantity and purity of the RNA was determined by electrophoresis and the ratio of the optical density at 260 nm to that at 280 nm. p53 was amplified by RT-PCR using the SuperScript™Ⅲ One-step RT-PCR system with Platinum ® Taq high fidelity kit (Invitrogen). Primers used for p53 were: forward, 5'-AGTCTAGAGCCACCGTCCA-3'; and reverse, 5'-TCT GACGCACACCTATTGCAAGC-3' (17). A total of 2 µl RNA was brought to a volume of 50 µl containing 25 µl 2X reaction mix, 1 µl SuperScript/Platinum Taq high fidelity enzyme mix, 1 µl of both sense and antisense primer. Amplification was performed as per the following conditions: one cycle of 55˚C for 30 min was performed to synthesize the cDNA. After denaturation at 94˚C for 2 min 40 cycles of PCR were performed to amplify p53 (denaturation at 94˚C for 15 sec, annealing at 58˚C for 30 sec, extension at 68˚C for 90 sec and a final extension of 68˚C for 5 min). The PCR products were analyzed by agarose gel electrophoresis.
The p53 amplicons were purified and linked with A tail by DNA A-tailing kit (Takara Bio, Dalian, China), then subcloned into pMD18-T vector. The DNAs were sequenced by using vector primers (Invitrogen). 
Results
Reduced expression of RhoE in human gastric, colorectal, lung and breast cancer tissues. Our laboratoty, previously, has reported that RhoA and RhoC expressions are significantly upregulated in gastric cancer tissues, and RhoE expression is likely regulated by epigenetic modification. We performed immunohistochemistry staining of cancer tissue microarrays that contain 74 gastric, 32 colorectal, 62 lung and 34 breast cancer carcinoma samples matched with adjacent normal tissues, respectively, in an effort to examine the protein expression of RhoE in human cancer tissues. The staining examination of the tumor tissues in comparison with the adjacent normal tissues showed that RhoE was abundantly expressed in the cytoplasm of the normal tissues but is at a low or non-detectable level in the cancer tissues in general (Fig. 1A) . We have attempted to quantify the relative RhoE expression levels based on parallel immunohistochemistry staining of the array chips by assigning a score ranging from '-', '+', '++' to '+++' that correspond to 1-4 in a blank-folded manner. This exercise yielded average staining scores of 1.99±0.28 (positive ratio was 41.9%), 2.45±0.35 (positive ratio was 68.7%), 2.19±0.19 (positive ratio was 71.0%) and 3.65±0.62 (positive ratio was 58.8%) for gastric, colorectal, lung and breast cancers, respectively, while the average staining scores of the adjacent tissues was 8.64±0.39 (positive ratio was 94.6%), 6.55±0.63 (positive ratio was 90.6%), 4.11±0.24 (positive ratio was 93.5%), 10.53±0.44 (positive ratio was 100.0%). The differences of the staining scores and positive ratios between the respective tumor tissues and the adjacent tissues were highly significant (p<0.005) (Fig. 1B) . Therefore, RhoE expression level appears to be inversely correlated with tumorigenesis in human gastric, colorectal, lung and breast cancers.
Since a possible divergence of the relative scores is related to different cancer progressive grades, we further examined RhoE expression levels in the tumor tissues based on the available cancer grades from the patient samples. Among the gastric, colorectal and lung cancer patient samples with known cancer grades, RhoE expression correlated well with the cancer grades (p<0.005). These analyses suggest that RhoE expression is also associated with cancer progression.
Enhanced RhoE expression inhibits cancer cell proliferation and invasion. The expression level of RhoE was investigated by western blot analysis in the ten different cancer cell lines. The data showed that RhoE protein expression was relatively higher in the cell lines HEK293, AGS, SMMC7721, LOVO, and A549, as well as NIH3T3 and COS7, while it was found at a relatively lower level in MKN45, SW480, HepG2 and SPCA1 cells (data not shown).
To explore the effects of RhoE on proliferation and invasion activities of cancer cells, the four RhoE low-expressed cell lines, MKN45, SW480, HepG2 and SPCA1, were transfected with pCDNA3.0-RhoE or pCDNA3.0, and the expression level of RhoE was detected by western blot analysis (Fig. 2B) . We found that the RhoE expressing cells displayed significantly reduced capability to invade through Matrigel-coated Transwells ( Fig. 2A) . Further, the growth rate of RhoE transfected cancer cell lines, in each case, was significantly slower than that of the control cells and the parental cells (Fig. 3) . These data suggest that RhoE expression can inhibit cell proliferation and suppresses invasion of the cancer cells.
Forced RhoE expression in cancer cells induces cell cycle arrest and apoptosis.
To assess if RhoE expression affects cancer cell proliferation by modulating cell cycle progression and/or survival, the RhoE transfectants were analyzed by fluorescence-activated cell sorting (FACS). The results showed that the percentage of G1 phase cells increased significantly with RhoE overexpression. Contrary to the empty plasmid transfected control cells, the RhoE overexpressed cells failed to transit through the G1/S check point when they were stimulated by 10% serum (Fig. 4A) . The TUNEL analysis and the Hoechest/PI stained cells also showed that the apoptosis rate of the RhoE expressing cells was significantly higher than that of the controls (p<0.01) (Fig. 4B) . Similar observations were made by visual imaging of caspase-3 positive cells (data not shown). These results provide evidence that RhoE overexpression not only induces cell growth arrest through inhibiting the G1/S phase transition, but also promotes apoptosis in the cancer cells.
RhoE expression is regulated by p53 transcription activity in cancer cell lines.
It was reported that RhoE promoter contained several p53-binding sites and RhoE was one of the p53 transcriptional target genes (9) . At the beginning of dissecting the mechanism of RhoE regulation in cancer, we determined a potential correlation of endogenous RhoE expression with p21-promoter-luc activities driven by cellular p53 in MKN45, SPCA1, SW480 and HepG2 cancer cell lines which also showed a relatively lower RhoE expression, and the luciferase/Renilla (Luc/Ren) ratios were significantly higher in cells with relatively high RhoE expression (p<0.05) (Fig. 5A) . These results suggest that RhoE expression could be associated with endogenous p53 transcription activity in the absence of the genotoxic stress. To determine whether forced p53 protein expression could cause the protein expression of RhoE, plasmids expressing PEGFP-wt-p53 or PEGFP-empty were transiently transfected into 4 cell lines with relatively low RhoE levels. Transfection efficiency was determined by counting the number of GFP-expressing cells per randomly chosen field of 100 cells at 24 h after transfection (multiple fields), and the mean number was determined as 45%. RhoE expression level was detected by western blot analysis while the trans fection efficiency was monitored by GFP expression (Fig. 5B) . The results revealed that the endogenous RhoE expression was increased significantly upon p53 expression in these cells. These results provide evidence that RhoE might be subject to p53 transcription regulation.
p53 mutation decreases the activity of RhoE promoter. To determine whether low RhoE expression was the effect of p53 mutation or deletion, we sequenced the coding regions of the endogenous p53 gene by RT-PCR in these RhoE low-expressed cancer cell lines. However, we only found one meaningful mutation in SW480 cells (codon 273) in which both the activity of p53 and the expression level of RhoE were lowest among the four cancer cell lines. These results indicated the possibility that the decreased p53 activity is related to the detected mutations in the cancer cells.
To confirm if p53 mutation could affect the RhoE expression, we generated EGFP-mt-p53 constructs which contained p53 hot point mutations (175, 248, 273, 282, 175/248, 175/273, 175/282, 248/273, 248/282, 273/282). These mutants together with RhoE-promoter-3000-luc and PRL-TK were co-transfected into PC3 cells (p53 null) and P21-promoter-luc was taken as positive control. We found that Luc/Ren ratios were significantly decreased in the cells which were transfected with EGFP-mt-p53 compared with that of EGFP-wt-p53. However, there was no difference between the mutants (Fig. 5C ). These results suggest that the p53 gene status is also a key factor affecting RhoE expression and p53 mutation could partly account for RhoE low expression. 
Discussion
Rho GTPases are important regulators of cell cytoskeleton organization and gene transcription, and deregulation of Rho family members has been shown to closely associate with the malignant phenotypes of cancer (18, 19) . While most Rho proteins are geranylgeranylated and are subject to GTP-hydrolysis regulation, RhoE is farnesylated and does not act as a classical GTPase switch without a detectable GTPase activity (6) . These biochemical findings suggest that RhoE may employ a unique regulatory mechanism and exhibits different function from other Rho family members. RhoA has been implicated in the regulation of cell morphology, motility, transformation, proliferation and tumorigenicity (20) (21) (22) (23) . Previous studies suggest that RhoE can function as an antagonist of RhoA signaling in two ways: one is to bind directly to ROCK1 (a RhoA target effector) and inhibit its activity; the other is to interact with p190B RhoGAP (a RhoA negative regulator) to reduce cellular level of RhoA-GTP (18, 24, 25) . Since RhoA is likely to play a positive role in cancer progression, we propose that RhoE might work in an opposite way. In our previous study, we found that RhoA was highly expressed in gastric cancer tissues and RhoA-specific small interfering RNA could partially reversed the malignant phenotypes of gastric cancer (26) . There are several studies on RhoE, and substantial research shows RhoE is downregulated in most cancers (7, 11, (27) (28) (29) , and there are also some studies indicated that RhoE is overexpressed and acts as a metastasis promoter in certain cancers (10, 12) . Here, we have evaluated RhoE protein expression patterns in four types of human cancer that are compared with the matched, adjacent tissues by immunohistochemistry, and the results showed that RhoE expression levels decreased significantly in each cancer, and in some cases RhoE appears to be completely absent from the tumors. Additionally, we found that RhoE expression level was inversely associated with the tumor differentiation grade. The .05) (C) P53 mutation decreased the activity of RhoE promoter. EGFP-mt-p53 constructs which contained p53 hot point mutations (175, 248, 273, 282, 175/248, 175/273, 175/282, 248/273, 248/282, 273/282) together with RhoE-promoter-3000-luc and PRL-TK were co-transfected into PC3 cells (p53 null). P21-promoter-luc was taken as positive control. Luc/Ren ratios were significantly decreased in the cells which were transfected with EGFP-mt-p53 than that of EGFP-wt-p53, but there was no difference among the mutants. Results are presented as mean ± SEM (n=3, * p<0.05).
differences seem to be more significant in breast and gastric cancer tissues, and less in lung cancer tissues.
To explore the effect of enhanced RhoE expression on the phenotypes of cancer cells, four cancer cell lines (MKN45, HepG2, SW480 and SPCA1) which show relatively lower RhoE expression were transfected with pcDNA3.0-RhoE. Overexpression of RhoE not only significantly inhibited the cancer cell proliferation, migration and invasion, but also induced apoptosis. These observations indicate that RhoE is intimately involved in many aspects of tumor progression and suggest the possibility that RhoE and its signaling cascade could serve as potential therapeutic target in anticancer treatment.
Since RhoE has a prominent effect on cancer cell proliferation, we thought that it might be involved in cell cycle and/or survival regulation. Our FACS analysis has shown that enhanced RhoE expression inhibited G1/S cell cycle transition and promoted apoptosis in the four tested cell lines. Previously, Villalonga et al (9) and Poch et al (30) also reported that RhoE could block G1 phase cell cycle progression in NIH3T3 cells and human glioblastoma U87 cells, while Bektic et al (31) found that RhoE could also induce a G2 block in prostate cancer cells (31, 32) . The differences may be due to different cancer types or cell lines used in the experiments.
Our unpublished data show that RhoE level does not change in response to serum stimulation. Since the study of Ongusaha et al indicated that RhoE was a pro-survival target gene of p53 which inhibits ROCK1-mediated apoptosis in response to genotoxic stress (16), we subsequently investigated the p53 activity by dual-luciferase reporter assay, and found that the transcription activity of p53 was low in the RhoE lowexpressed cancer cell lines and high in the high RhoE expressed cancer cell lines. Furthermore, in each of the four examined cell lines with relatively low RhoE expressions (MKN45, HepG2, SW480 and SPCA1), we also found exogenous p53 expression significantly enhanced the RhoE expression. Taken together, these findings confirm that the expression of RhoE was regulated by p53. p53 activity can be regulated by numerous factors in cells, and loss of function mutations is prominent in the reduction of its tumor surveillance function. p53 gene mutation was found in >50% of all types of human cancers and >80% were missense mutations that lead to the synthesis of a stable full-length protein (33) . At the beginning of understanding the reason of the significant differences of p53 activities in different cancer cell lines, we have examined p53 mutations in 9 cancer cell lines and found only one meaningful mutation in SW480, and the activity of p53 and the expression level of RhoE were both the lowest in this cell line. These results, coupled with the demonstration that increased functional p53 expression could increase RhoE protein level in cells, suggest that p53 mutations in cancer cells may be related to the low expression of RhoE. To demonstrate this hypothesis, 10 kinds of PEGFP-mt-p53 vectors with the hot points of p53 mutation were generated. We found that Luc/Ren ratios were significantly lower in the cells which were transfected with EGFP-mt-p53 than that of EGFP-wt-p53, and there was no difference between the mutants. These results suggest that RhoE expression could not only be associated with p53 transcription but also be affected by p53 mutation.
Previous cell biology studies have suggested that RhoE was able to bind to ROCK1 and to inhibit ROCK-induced myosin phosphatase phosphorylation (25) . ROCK1 is a RhoA downstream target known to mediate actin stress fiber assembly, whereas RhoE was found to antagonize RhoA to induce stress fiber disassembly (18, 19) . RhoE could also be phosphorylated by ROCK1, leading to an increased stability and altered cellular localization. Another study has shown that expression of RhoE leads to decreased cellular RhoA-GTP by increasing the GAP activity of p190B RhoGAP (18) . Here we have shown that RhoE expression can be regulated by p53 transcription activity. We have verified that p-MLC level, an indicator of endogenous RhoA-ROCK signal, decreased in the RhoE-transfectant cancer cells (data not shown). Therefore, it is possible that RhoE mediate signals from p53 and serves as an antagonism of RhoA signaling in these cancer cells through a direct or indirect interaction with p190B RhoGAP or ROCK1.
In summary, RhoE expression was found significantly reduced in human gastric, colorectal, lung and breast carcinoma tissues compared to that of the adjacent normal tissues. Increased RhoE expression in these cancer cell lines resulted in an inhibition of proliferation, migration and invasion, and induced cell apoptosis. RhoE expression could be regulated by p53 transcription and decreased by p53 mutation. Our findings strongly suggest that RhoE can act as a candidate tumor suppressor and serve as a marker of cancer classification or progression.
